Literature DB >> 19654857

Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions.

Rianne van den Berg1, Ingrid van Hoogstraten, Michiel van Agtmael.   

Abstract

Hyporesponsiveness (anti-HBs 10-100 IU/l) or non-responsiveness (anti-HBs < 10 IU/l) to hepatitis B vaccines is a problem in approximately 20-70% of HIV-positive patients. Mechanisms for impaired humoral and cellular immunity related to the HIV infection are reviewed. Contributing risk factors like age, gender, CD4+ T-cell count, HIV RNA load and coinfection with hepatitis C are highlighted. New developments in improving the HBV vaccine immunogenicity are discussed and clinical recommendations are given for HBV-re-vaccination of HIV patients who failed on standard HBV vaccination.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19654857

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  21 in total

Review 1.  Immunization of HIV infected children.

Authors:  Jagdish Chandra; Dinesh Yadav
Journal:  Indian J Pediatr       Date:  2012-02-10       Impact factor: 1.967

Review 2.  Hepatitis B virus vaccination in HIV-infected people: A review.

Authors:  François-Xavier Catherine; Lionel Piroth
Journal:  Hum Vaccin Immunother       Date:  2017-02-16       Impact factor: 3.452

3.  Production of highly concentrated, heat-stable hepatitis B surface antigen in maize.

Authors:  Celine A Hayden; Erin M Egelkrout; Alessa M Moscoso; Cristina Enrique; Todd K Keener; Rafael Jimenez-Flores; Jeffrey C Wong; John A Howard
Journal:  Plant Biotechnol J       Date:  2012-07-21       Impact factor: 9.803

Review 4.  Vaccination in HIV-infected adults.

Authors:  Nancy F Crum-Cianflone; Mark R Wallace
Journal:  AIDS Patient Care STDS       Date:  2014-07-16       Impact factor: 5.078

5.  Efficacy of Hepatitis B Vaccination among Children in Special Region of Yogyakarta, Indonesia: Evaluation of Humoral and Cellular Immunity.

Authors:  Caessar Pronocitro; Nenny Sri Mulyani; Afif Avicenna Ghufron; Yugata Halimawan Hazazi; Bambang Ardianto; Didik Setyo Heriyanto
Journal:  Kobe J Med Sci       Date:  2018-01-17

6.  Delayed-type hypersensitivity and hepatitis B vaccine responses, in vivo markers of cellular and humoral immune function, and the risk of AIDS or death.

Authors:  Shane B Patterson; Michael L Landrum; Jason F Okulicz
Journal:  Vaccine       Date:  2014-04-29       Impact factor: 3.641

Review 7.  Clinical impact of hepatitis B and C virus envelope glycoproteins.

Authors:  Hélène Jeulin; Aurélie Velay; John Murray; Evelyne Schvoerer
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

Review 8.  Phage display creates innovative applications to combat hepatitis B virus.

Authors:  Wen Siang Tan; Kok Lian Ho
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

9.  Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya.

Authors:  Elizabeth Irungu; Nelly Mugo; Kenneth Ngure; Robert Njuguna; Connie Celum; Carey Farquhar; Shireesha Dhanireddy; Jared M Baeten
Journal:  J Infect Dis       Date:  2012-11-21       Impact factor: 5.226

10.  Association between hepatitis B vaccine antibody response and CD4 reconstitution after initiation of combination antiretroviral therapy in HIV-infected persons.

Authors:  Kahtonna Allen; Octavio Mesner; Anuradha Ganesan; Thomas A O'Bryan; Robert G Deiss; Brian K Agan; Jason F Okulicz
Journal:  BMC Infect Dis       Date:  2015-05-01       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.